Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM 71 Price-to-Tangible-Book is 2.53 as of Aug. 08, 2026, which is 8% below its 10-year median of 2.74. GuruFocus rates LTS:0RAM with a GF Score™ of 71/100 and a GF Value™ of kr25.96 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 837 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 55.08% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Price-to-Tangible-Book or its related term are showing as below:
LTS:0RAM'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86 Med: 2.74 Max: 4.02
Current: 2.52
During the past 13 years, Vistin Pharma ASA's highest Price to Tangible Book Ratio was 4.02. The lowest was 0.86. And the median was 2.74.
LTS:0RAM's Price-to-Tangible-Book is ranked worse than 55.08% of 837
companies
in the Drug Manufacturers industry
Industry Median: 2.24
vs LTS:0RAM: 2.52
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Vistin Pharma ASA Price-to-Tangible-Book Related Terms
Vistin Pharma ASA Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Vistin Pharma ASA (LTS:0RAM) has a Price-to-Tangible-Book of 2.53 as of Aug. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Vistin Pharma ASA and its competitors. This is near median its historical median of 2.74. Over the past decade, Vistin Pharma ASA's Price-to-Tangible-Book has ranged from 0.86 to 4.02. According to the industry distribution chart, Vistin Pharma ASA ranks #461 out of 837 companies in the Drug Manufacturers industry, placing it in the top 55.1%.
Is Vistin Pharma ASA's Price-to-Tangible-Book too high?
Vistin Pharma ASA's current Price-to-Tangible-Book of 2.53 is near median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 4.02. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.24. Vistin Pharma ASA's value of 2.53 is 12.9% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #461 out of 837 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #461 out of 837 companies for Price-to-Tangible-Book. This places Vistin Pharma ASA in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.24. Vistin Pharma ASA's value of 2.53 is 12.9% above this benchmark. Historically, Vistin Pharma ASA's own Price-to-Tangible-Book has ranged from 0.86 to 4.02 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 2.24, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.24, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Price-to-Tangible-Book of 2.53 is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Price-to-Tangible-Book is 2.53, which is near median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.96, compared to a current price of kr20.00 — trading 23% below its estimated fair value. The current Price-to-Tangible-Book is 2.53, which is near median its 10-year median of 2.74 and 12.9% above the Drug Manufacturers industry median of 2.24. Vistin Pharma ASA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Price-to-Tangible-Book is 2.53 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.00 is trading 23% below its estimated GF Value™ of kr25.96.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Price-to-Tangible-Book: 2.53 (near median its 10-year median of 2.74)
GF Value™: kr25.96 vs. price of kr20.00 (23% below fair value)
Industry Position: 12.9% above the Drug Manufacturers median (#461 of 837)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
71GF Score
Get the complete analysis for LTS:0RAM
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
